Kestra Medical Technologies, Ltd. $KMTS Shares Sold by Omega Fund Management LLC

Omega Fund Management LLC cut its holdings in shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) by 16.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,373,591 shares of the company’s stock after selling 272,302 shares during the quarter. Kestra Medical Technologies comprises 12.7% of Omega Fund Management LLC’s investment portfolio, making the stock its 5th largest holding. Omega Fund Management LLC owned approximately 2.35% of Kestra Medical Technologies worth $36,428,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of KMTS. Brown Advisory Inc. raised its stake in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of Kestra Medical Technologies by 13.7% in the third quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock valued at $35,449,000 after purchasing an additional 179,885 shares in the last quarter. Eventide Asset Management LLC raised its stake in shares of Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock valued at $33,671,000 after purchasing an additional 65,288 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after purchasing an additional 612,343 shares in the last quarter. Finally, Federated Hermes Inc. raised its stake in shares of Kestra Medical Technologies by 31.3% in the fourth quarter. Federated Hermes Inc. now owns 525,000 shares of the company’s stock valued at $13,923,000 after purchasing an additional 125,000 shares in the last quarter.

Insiders Place Their Bets

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $20.96, for a total value of $314,400.00. Following the sale, the insider directly owned 334,786 shares in the company, valued at $7,017,114.56. This represents a 4.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 3.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on KMTS. BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th. Weiss Ratings lowered Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. Finally, The Goldman Sachs Group cut their target price on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $27.40.

Kestra Medical Technologies Stock Performance

Shares of NASDAQ:KMTS opened at $19.23 on Wednesday. The business’s fifty day moving average price is $20.70 and its two-hundred day moving average price is $22.97. Kestra Medical Technologies, Ltd. has a fifty-two week low of $13.25 and a fifty-two week high of $30.00. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -4.86 and a beta of 0.83. The company has a debt-to-equity ratio of 0.15, a current ratio of 7.32 and a quick ratio of 7.32.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The company had revenue of $24.55 million during the quarter. The company’s revenue was up 62.7% compared to the same quarter last year. As a group, analysts predict that Kestra Medical Technologies, Ltd. will post -2.34 EPS for the current fiscal year.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.